• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Phreesia Looks to Help Doctors Fill Cancelation Slots

Share:

July 16, 2021

Phreesia, a digital health startup focused on the scheduling space, is looking to tackle the appointment no-show problem with a new tool called Appointment Accelerator, which is able to automatically fill canceled appointments.

The way it works is, the company’s AI and custom-rules engine-backed product is able to send patients with appointments scheduled weeks or months away, offering them an earlier time slot.

The company is pitching this as a way to cut down on the time it takes to fill a canceled appointment, claiming that the average time it takes practices to fill a slot using this system is 5.3 minutes.

WHY IT MATTERS

According to the Healthcare Innovation Group, the annual cost of missed appointments in the U.S. is roughly $150 billion. The organization projects that each no-show typically costs the physician 60 minutes and $200.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

Digital tools have been used in the past to help remind patients about a visit or get confirmation about an upcoming appointment.

“Appointment Accelerator is an exciting extension of Phreesia’s mission to create a better, more engaging healthcare experience for patients, providers, and staff,” Phreesia CEO Chaim Indig, said in a statement.

“Given that so many Americans skipped or delayed medical care during the pandemic, we believe it’s more important than ever to help practices improve efficiency to ensure patients get care faster.”

THE LARGER TREND

In 2019 Phreesia joined a small group of digital health companies exiting via an IPO. The stock saw early success on the stock market. Its initial asking price was $18, and by the end of its first day on the market, it was trading 40-50% above its initial asking price. Today the stock is worth roughly $64 per share.

Phreesia isn’t the only company working in the cancelation space. T-Pro launched eClinic Manager, a platform that enables clinicians to carry outpatient appointments virtually on a smartphone in order to avoid cancelation. The tool includes a virtual waiting room.

In 2016 QueueDr landed $1.2 million for its text messaging service that helps fill last-minute cancelations. Since then Phreesia has acquired QueueDr.

Editor’s note: A previous version of the story incorrectly stated that the service texted patients on a waitlist. The story has been ammended.

Source: Mobihealthnews

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • MedPlast’s Acquisition of Integer Holdings’ Advanced Surgical & Orthopedics BusinessMedPlast’s Acquisition of Integer Holdings’ Advanced Surgical & Orthopedics Business
  • Medtronic to Acquire MedicreaMedtronic to Acquire Medicrea
  • Temp Pal Smart Thermometer Helps Reduce COVID-19 Spread in HospitalsTemp Pal Smart Thermometer Helps Reduce COVID-19 Spread in Hospitals
  • Azeria Therapeutics Announces £32.0 Million Series B FinancingAzeria Therapeutics Announces £32.0 Million Series B Financing
  • Corundum Neuroscience Launches Neuroscience Venture Builder & FundCorundum Neuroscience Launches Neuroscience Venture Builder & Fund
  • Cancer and Neuroscience Led 2023 VC, M&A Investment in BiopharmaCancer and Neuroscience Led 2023 VC, M&A Investment in Biopharma
  • Mesa Labs Acquires Gyros Protein TechnologiesMesa Labs Acquires Gyros Protein Technologies
  • Goldcup 34064 AB Announces Vironova BioAnalytics Acquired by Investor GroupGoldcup 34064 AB Announces Vironova BioAnalytics Acquired by Investor Group

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications